Skip to main content
SyntekaBio,Inc. logo

SyntekaBio,Inc. — Investor Relations & Filings

Ticker · 226330 ISIN · KR7226330009 KO Professional, scientific and technical activities
Open in API
Filings indexed 322 across all filing types
Latest filing 2025-03-07 AGM Information
Country KR South Korea
Listing KO 226330

About SyntekaBio,Inc.

https://www.syntekabio.com/

SyntekaBio is an AI-driven drug discovery company that utilizes its proprietary supercomputing infrastructure, the AI Bio-Supercom Center, to accelerate pharmaceutical development. The company's core technology, the DeepMatcher® platform, underpins a suite of services for discovering small molecules, antibodies, and neoantigens for personalized cancer vaccines. A key offering is LaunchPad, a factory-like system that continuously generates a stream of 'off-the-shelf' drug candidates for numerous disease targets, aiming to expedite the path to IND-enabling studies. SyntekaBio delivers its solutions through comprehensive discovery partnerships and a modular, cloud-based Software as a Service (SaaS) platform, STB CLOUD, providing researchers with automated tools for drug development and genomics analysis.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company is holding its AGM on a date that coincides with other companies' meetings. Since it is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves, the proxy statement, or the voting results, it falls under the general regulatory filing category.
2025-03-07 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Syntekabio. It contains the meeting agenda, details on electronic voting, board activity reports, and financial statements (balance sheet, income statement) for the 16th fiscal year. This document is a formal proxy statement and meeting notice sent to shareholders to solicit votes for the upcoming AGM, which fits the definition of a Proxy Solicitation & Information Statement.
2025-03-07 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (often referred to as a Proxy Solicitation Statement). It contains information regarding the upcoming Annual General Meeting (AGM), including the agenda, voting procedures, and proxy solicitation details. While it includes financial statements, these are provided as supplementary information for the shareholders' meeting, not as a standalone Annual Report or 10-K. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2025-03-07 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Syntekabio) announcing a significant change (over 15-30%) in its financial structure (revenue, operating profit, net income) compared to the previous fiscal year. This is a standard regulatory disclosure requirement in the Korean market (DART system) for material financial changes. Since it is an initial announcement of financial results highlights rather than a full annual report or a simple report publication notice, it falls under the Earnings Release category. FY 2024
2025-02-17 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options). It details the issuance of stock options to employees and related parties, including the number of shares, exercise price, and board resolution details. In the context of Korean corporate filings (DART system), this is a specific regulatory disclosure regarding capital/equity changes related to stock options, which falls under the 'Regulatory Filings' category as it is a mandatory disclosure of a corporate action that does not fit into the other specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes).
2025-02-17 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) between Syntekabio and Kymera Therapeutics. It details the contract value, duration, and terms. Since this is a specific regulatory announcement of a business contract and does not fit into the other specialized categories like M&A or financial reports, it is classified as a general Regulatory Filing (RNS).
2025-02-11 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.